Morrison G, Morrison J M, Redmond A O, Byers C A, McCracken K J, Dodge J A, Guilford S A, Bowden M W
Royal Belfast Hospital for Sick Children, Belfast, UK.
Aliment Pharmacol Ther. 1992 Oct;6(5):549-55. doi: 10.1111/j.1365-2036.1992.tb00569.x.
This study compared the relative effectiveness of a standard pancreatic enzyme supplement ('Creon', Duphar) and a new preparation ('Pancrease HL', Cilag) containing about 3 times the lipase and more than 5 times the protease activity. Capsule dosage was adjusted to a ratio of approximately 3:1. Fat balances showed that absorption of fat did not change significantly on conversion to the new high-lipase product, and the coefficient of absorption of total energy was similarly maintained. The coefficient of protein absorption was significantly enhanced with the high enzyme preparation (P less than 0.01), which may explain the reported subjective improvement in stool odour. No adverse effects were recorded. Patient acceptability of the new compound was high; the great reduction in the number of capsules required at each meal was cited by all patients as the reason for their preference.
本研究比较了标准胰酶补充剂（“得每通”，杜法尔公司）与一种新制剂（“胰酶HL”，西拉格公司）的相对疗效，新制剂的脂肪酶活性约为前者的3倍，蛋白酶活性超过前者的5倍。胶囊剂量调整为约3:1的比例。脂肪平衡显示，转换为新的高脂肪酶产品后，脂肪吸收没有显著变化，总能量吸收系数也同样保持稳定。高酶制剂使蛋白质吸收系数显著提高（P<0.01），这可能解释了报告中粪便气味主观改善的原因。未记录到不良反应。新化合物的患者接受度很高；所有患者都提到每餐所需胶囊数量大幅减少是他们偏好的原因。
